Endovia Health Sciences, Inc. EDVA PHARMA
Company Overview
Endovia Health Sciences, Inc. engages in the manufacturing, distribution, marketing, and sale of various beverages in the United States. It operates in two segments Manufacture and Distribution of Non-Alcoholic and Alcoholic Beverages, and Retail Sale of Beverages and Groceries Online. The company offers flavored tequilas under the Chispo Tequila brand name; wine under the Copa DI Vino brand name; and sangria under the Pulpoloco Sangria brand name. It distributes its products through the business-to-business and business-to-consumer e-commerce distribution platform. The company was formerly known as Splash Beverage Group, Inc. and changed its name to Endovia Health Sciences, Inc. in August 2026. The company is based in Fort Lauderdale, Florida.
Why Investors Should Care
Return on capital employed stands at 130.6%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $73.07K (-90.9% YoY); net profit $-25.23M.
- Trailing 12 Months Year-on-year growth — revenue -90.9%.
- 5-Year Trend Long-term compounding — revenue CAGR -84.1%, profit CAGR -5.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -84.07% |
| 1 Year: | -90.88% |
Compounded Profit Growth
| 5 Years: | -5.45% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -97.70% |
| 6 Months: | -85.35% |
| 3 Months: | -51.52% |
| 1 Month: | -15.79% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.52 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 130.6%.
- Generates positive free cash flow.
CONS
- Revenue declined at -84.1% CAGR over 5 years.
- Earnings shrank at -5.4% CAGR over 5 years.
- Trading 98.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | EDVA Endovia Health Sciences, Inc. PHARMA | 0.16 | -0.01 | $1.11M | 0.00% | 130.64% | - | -84.07% | -5.45% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 692.97K | - | - | 2.83M | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | -365.21K | 4.22K | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | -412.55K | 2.38K | 0 |
| Gross Profit | 84.61K | 83.67K | 85.96K | 119.91K | 86.06K | 100.03K | 133.34K | 122.49K | 122.49K | 104.54K | 121.72K | 170.35K | 174.45K | 207.73K | 165.08K | -10.44K | -5.44K | -13.95K | 4.79K | 193.98K | 343.94K | 517.42K | 905.05K | 819.85K | 1.29M | 1.35M | 1.77M | 1.76M | 1.78M | 1.30M | 163.62K | 244.43K | 291.02K | - | - | 0 | 0 | 47.34K | 1.85K | 0 |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.50M | 9.54M | 1.02M | 980.82K | 2.01M |
| Operating Income | 15.37K | -2.52K | -6.18K | 254 | -15.92K | -19.77K | 11.79K | -12.23K | -12.23K | -61.24K | -21.59K | 33.07K | 15.95K | 68.48K | -2.21K | -448.48K | -308.15K | -861.60K | -1.55M | -415.48K | -2.16M | -4.55M | -6.71M | -12.07M | -5.68M | -5.83M | -5.11M | -3.45M | -4.22M | -4.32M | -3.25M | -3.69M | -2.67M | - | - | -1.50M | -9.54M | -976.41K | -978.97K | -2.01M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -7.06M | -9.43M | -1.21M | -1.23M | -1.76M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.30M | 345.67K | 1.11M | 902.90K | 244.47K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -8.36M | -9.89M | -2.32M | -2.14M | -2.01M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | 14.42K | -5.10K | -6.64K | -883 | -15.55K | -18.92K | 12.08K | -11.85K | -11.85K | -61.92K | -19.13K | 35.41K | 20.01K | 67.71K | -4.99K | -703.62K | -218.39K | -53.98K | -3.45M | -373.35K | -2.08M | -4.44M | -6.56M | -12.17M | -5.99M | -5.76M | -5.14M | -3.73M | -5.61M | -5.67M | -4.67M | -5.33M | -4.72M | - | - | -8.49M | -9.89M | -3.21M | -2.14M | -2.05M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.19 | - | - | -0.16 | -0.16 | -0.14 | - | -0.13 | -0.13 | - | - | - | - | -7.88 | -1.83 | -18.04 | - | -1.88 | -0.79 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 475.25K | 605.90K | 897.34K | 1.01M | 895.35K | 1.31M | 20.39K | 2.30M | - | 18.09M | 18.85M | 801.27K | 73.07K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | 12.17M | 13.28M | 921.07K | 56.17K |
| Gross Profit | 238.98K | 349.85K | 470.36K | 527.38K | 454.93K | 703.90K | -225.11K | 363.59K | - | 5.92M | 5.57M | -119.80K | 16.90K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 27.31M | 20.86M | 9.78M | 14.20M |
| Operating Income | 618 | -27.88K | 18.90K | -50.00K | -157.21K | 66.67K | -4.49M | -17.66M | - | -21.39M | -15.29M | -9.90M | -14.19M |
| EBITDA | - | - | - | - | - | - | - | - | - | -20.45M | -14.77M | -9.83M | -19.97M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 251.50K | 5.69M | 7.38M | 4.37M |
| Pretax Income | - | - | - | - | - | - | - | - | - | -21.64M | -21.00M | -17.61M | -24.35M |
| Tax Provision | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Net Income | - | -30.09K | 19.15K | -48.85K | -147.53K | 68.21K | -5.14M | -28.67M | - | -21.69M | -21.00M | -23.76M | -25.23M |
| Diluted EPS | - | - | - | - | - | 0.01 | -0.04 | -1.06 | - | -92.80 | -79.16 | -70.72 | -47.88 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 95.72K | 166.71K | 239.75K | 355.33K | 241.03K | 408.30K | 605.31K | 9.23M | - | 17.30M | 9.90M | 2.76M | 965.69K |
| Current Assets | - | - | - | - | - | - | - | - | - | - | 10.66M | 3.98M | 1.90M | 631.99K |
| Cash & Equivalents | - | - | - | - | - | - | 938.04K | 42.64K | 380.00K | - | 4.43M | 379.98K | 13.79K | 281.44K |
| Inventory | - | - | - | - | - | - | - | - | - | - | 3.72M | 2.25M | 319.10K | 33.54K |
| Receivables | - | - | - | - | - | - | - | - | - | - | 1.81M | 890.63K | 191.99K | 15.75K |
| Total Liabilities | - | 155.36K | 187.35K | 241.23K | 315.67K | 313.89K | 410.95K | 10.36M | 9.33M | - | 7.98M | 15.50M | 21.39M | 16.27M |
| Current Liabilities | - | 137.58K | 158.58K | 220.06K | 290.36K | 299.88K | 405.46K | 10.28M | 5.42M | - | 4.97M | 14.75M | 19.37M | 16.26M |
| Long Term Debt | - | 17.78K | 28.77K | 21.17K | 25.30K | 14.01K | 5.50K | 2.06K | 1.24M | - | 2.54M | 457.66K | 1.97M | 3.42K |
| Total Debt | - | - | - | - | - | - | - | - | - | - | 4.37M | 9.35M | 12.31M | 6.67M |
| Total Equity | -90.32K | -59.65K | -20.64K | -1.49K | 39.67K | -72.86K | -7.83M | -9.76M | -9.35M | - | 9.32M | -5.61M | -18.63M | -15.30M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | 256.78K | 277.06K | 417.46K | 749.70K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -35.65K | 1.22K | 13.07K | 32.11K | -17.60K | 62.39K | -2.66M | -21.32M | - | -14.07M | -10.19M | -7.80M | -4.79M |
| Investing Cash Flow | - | -30.39K | -20.59K | -52.08K | -42.23K | -67.57K | -12.55K | -768.62K | - | -102.70K | -14.11K | 0 | 0 |
| Financing Cash Flow | 28.97K | 53.41K | -10.05K | 74.28K | 16.09K | -5.76K | 1.78M | 22.49M | - | 14.45M | 6.15M | 7.54M | 5.10M |
| Capital Expenditure | - | - | - | - | - | - | - | - | - | -102.70K | -14.11K | -3.23K | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | -14.18M | -10.20M | -7.80M | -4.79M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | 270.83K | -4.06M | -251.14K | 315.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 50.3% | 57.7% | 52.4% | 52.1% | 50.8% | 53.8% | -1,104.2% | 15.8% | - | 32.7% | 29.5% | -15.0% | 23.1% |
| Operating Margin % | 0.1% | -4.6% | 2.1% | -4.9% | -17.6% | 5.1% | -22,009.4% | -767.9% | - | -118.3% | -81.1% | -1,235.6% | -19,415.6% |
| Net Margin % | - | -5.0% | 2.1% | -4.8% | -16.5% | 5.2% | -25,191.2% | -1,246.7% | - | -119.9% | -111.4% | -2,964.9% | -34,537.0% |
| ROE % | - | 145.8% | -1,289.8% | -123.1% | 202.5% | -0.9% | 52.6% | 306.7% | - | -232.7% | 374.7% | 127.5% | 164.9% |
| ROCE % | -1.5% | -342.7% | 96.0% | -77.0% | 267.1% | 2,348.5% | 46.4% | -463.5% | - | -173.4% | 315.1% | 59.6% | 92.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC | 0.79% | 87.11K | $13.59K |
| 2 | Phraction Management LLC | 0.28% | 30.91K | $4.82K |
| 3 | Summit Trail Advisors, LLC | 0.23% | 25.00K | $3.90K |
| 4 | Truist Financial Corp | 0.15% | 16.95K | $2.64K |
| 5 | Geode Capital Management, LLC | 0.15% | 17.15K | $2.67K |
| 6 | Compass Financial Management LLC | 0.15% | 16.12K | $2.52K |
| 7 | Lifetime Wealth Management P.c. | 0.15% | 16.51K | $2.58K |
| 8 | Virtu Financial LLC | 0.14% | 14.97K | $2.33K |
| 9 | Point72 Asset Management, L.P. | 0.13% | 14.24K | $2.22K |
| 10 | HRT Financial LP | 0.13% | 14.17K | $2.21K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for EDVA
Eregli Demir Ve Celik Fabrikala (EDVA.SG) Q2 FY2026 earnings call transcript - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxNTXc1eWRRY3pXeUtabWpPUXlqa2I1azlSUkZYNTEwYVYxajUwSmhNOU9zV1F0OVJYMlFuS2JxemxvVmZ5ejVzNzBrd2oyekU3XzNDc2hZVjRldXZFWXVnYnhjY2RxQ21aWFNXTDJsSGlWNkVOcWNDU2t1alFKUlR3V0dXSHRUWjM5MVFCcD…
EDVA Stock Price and Chart — AMEX:EDVA - TradingView
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE1Pa183YnBGdjhubFIzMXkyaUJnN1RkZHh2MmxwZGZXQnZzV2RpY0pHX2pkT195RDFrbWhRYlY0M2Z3anBoRERrVUJTQWc2d3BtV1owTzhGME12UQ?oc=5" target="_blank">EDVA Stock Price and Chart — AMEX:EDVA</a>&nb…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE5LX0FQLWRaMXhuVUFSVlBiWnROYkNpQndRbTMxcGtzYzBRX3M5bGFQOGJ4VThNTF9WVlpvRDVTR1M3cFdfT2xJTm5oVWtxQjdR?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
A fund reports a passive stake above 5% in Endovia Health Sciences (EDVA). - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQRDVTQ3A0cVNpUV9hbHBOS0hrcHowYWM0MEg2R3dVZHRwZlIyU1dRenJvLXh3SEdMSEotNmZXZkdoNkktdTl0dEFlYzhhWFhGa25WSUgwX05rbWUyWU1zRVUwN2JMMFRoRW13RXRKWGxBTTZSODFLZVdnMzJpSDVldnd0aHhMSjktVWc0VV…
Endovia Health Sciences, Inc. (EDVA) stock price, news, quote and history - Yahoo Finance Singapore
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE1HdlFNdFpqbjFkamRONlNEd3d5ZFp0LU5vZlpHeVp3Uy1PZ0dOSFZuWkJtcEJuUWcyUThtNVFZREY2RkJtT2NTMmctRFpLUXhqbkE?oc=5" target="_blank">Endovia Health Sciences, Inc. (EDVA) stock price, news, …
Endovia Health Sciences (EVDA) Stock Soars 48% After-Hours: Here's What's Going On - Benzinga
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPNUo5bW5DQlR6NjVkMDZFN0l4WHJ0SVl4UmhaM0V2WFJvb2VNeFA1Rm9IQzBvUF9meldZRmdLR3hRN1FCcm50T3RVRjdkNVRfRXA1NTNjWFV4UU9PZ25MckJjNUZidGJNRHYwLVVIOUQxLVZoY2dvT19zazZVenNra0l3QUZpWmIxN3FELX…
EDVA — Frequently Asked Questions
What is the current share price of Endovia Health Sciences, Inc. (EDVA)?
As of 2026-10-23 16:27 PDT, Endovia Health Sciences, Inc. (EDVA) trades at $0.16 on NYSE American. Its 52-week range is $0.14 to $10.16.
What is the market capitalisation of EDVA?
Endovia Health Sciences, Inc. (EDVA) has a market capitalisation of $1.11M on NYSE American.
What is the P/E ratio of EDVA?
EDVA trades at a trailing price-to-earnings (P/E) ratio of -0.01. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is -0.06.
Is EDVA a good stock to buy?
This page provides a data-driven analysis of Endovia Health Sciences, Inc. (EDVA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.